Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients from 2 to less than 7~* Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria~* Criteria met for ASD on Autism Diagnostic Observation Schedule-Generic (ADOS-2) and Autism Diagnosis Interview Revised (ADI-R)~* CGI (Clinical Global Impression) - Severity rating Score ≥ 4~* Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34~* Social responsiveness Scale second edition (SRS-2) total score ≥ 66 T-Score~* Absence of diagnosis of Fragile X or Rett Syndrome~* Absence of any clinically significant abnormality likely to interfere with the conduct of the study according to the judgment of the investigator.~Exclusion Criteria:~* Patients not able to follow the study assessments defined by the protocol, with the exception of self-rating questionnaires which will be assessed by parent/legal representative/caregiver for those patients unable to complete them~* Patients having a high suicidal risk according to the investigator judgement~* Chronic renal dysfunction~* Chronic cardiac dysfunction~* Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural therapy~* Severe electrolyte imbalance that is likely to interfere with the study conduct or evaluation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- BUMETANIDE (S95008) followed by Open-Label S95008 (Type: EXPERIMENTAL): Participants will receive S95008 for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
- PLACEBO followed by Open-Label S95008 (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.

Based on this trial design, predict the completion outcome and termination type (if applicable).